Pfizer’s respiratory syncytial virus vaccine was more than 90% effective among older adults during the first season it was available, including among those with underlying conditions or severe disease ...
As respiratory virus season begins, pediatric experts are preparing for an expected rise in cases of Respiratory Syncytial ...
The respiratory syncytial virus vaccine is effective in reducing emergency visits, hospitalizations, and severe illness in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback